Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Alzheimer’s disease biomarkers predict rapid cognitive decline in very old adults

Cognitive decline in very old adults has been considered for decades to be an almost inevitable consequence of aging.

1 Jul 2026

New AI framework outperforms conventional biomarkers in predicting cancer survival

Digestive system cancers, including hepatobiliary and gastrointestinal malignancies, remain a major global oncological burden. Although immune checkpoint inhibitors have changed the treatment landscape for some patients, their overall efficacy remains limited, with only about 15% to 30% of patients achieving durable clinical benefit.

1 Jul 2026

Blood biomarker may predict Alzheimer's progression differently in men

A blood test does not lie, exactly. It reports a number. The question raised by a new mini-review in Brain Medicine, which gathers and weighs a decade of scattered findings, is whether clinicians have been reading the same number in two different ways without realizing it.

30 Jun 2026

Study links DNA methylation to aggressive prostate cancer behavior

The prostate is the single organ most frequently afflicted by cancer in men. Prostate cancer affects approximately 4 million American men, with another 330,000 men expected to be diagnosed with the condition this year alone.

30 Jun 2026

Experts reframe steatotic liver disease as a dynamic continuum

The classification of steatotic liver disease (SLD) is undergoing a major conceptual transformation. In a recent article published in eGastroenterology, Dr. Chen, Dr. Horn, and Prof. Tacke from Charité - Universitätsmedizin Berlin argue that metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD) should not be regarded as rigid diagnostic categories, but rather as interconnected and evolving disease trajectories.

30 Jun 2026

Altering gut microbes could improve immunotherapy responses in liver cancer

Immune checkpoint blockade (ICB) has reshaped the treatment landscape for advanced hepatocellular carcinoma (HCC), offering new hope where few options existed.

30 Jun 2026

New diagnostic tool bypasses blood-brain barrier to detect autism early

A study published in NeuroMarkers showed that a nanosensor can measure nitric oxide (NO) from patient-derived stem cells to distinguish autism spectrum disorder (ASD) from intellectual disability (ID), even when both conditions share the exact same genetic mutation.

30 Jun 2026

Blood metabolism maps how lifestyle tracks function in cognitive aging

A new study used pathway-level blood metabolomics to identify lifestyle-associated metabolic patterns linked to physical, cognitive, and daily functional performance across CN, MCI, and AD. The findings suggest that diet- and activity-linked pathway signals span energy, amino acid, lipid, inflammatory, oxidative stress, and microbiome-related metabolism, but require independent and longitudinal validation.

29 Jun 2026

New drug candidate reduces toxic protein clumps of Huntington's disease

An experimental drug has been shown to alleviate symptoms of Huntington's disease and extend lifespan in mouse models. Further studies are required to determine whether these results may also apply to humans.

29 Jun 2026

Engineered CAR T cells successfully target bladder cancer in mice

Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center, and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill bladder cancer cells.

26 Jun 2026

Artificial intelligence improves diagnostic accuracy in clinical breast pathology

Artificial intelligence (AI) is increasingly reshaping diagnostic pathology, with breast pathology representing one of the most advanced and clinically impactful areas of adoption.

26 Jun 2026

Biognosys showcases next-gen multiomics innovations at ASMS 2026

The Biognosys Group, a leader in mass spectrometry-based multiomics, announces advancements across its integrated multiomics portfolio, highlighting next-generation software, sample preparation, enrichment, and separation technologies for proteomics and metabolomics.

From Biognosys 26 Jun 2026

Gut microbes emerge as potential players in estrogen-driven cancers

A new review maps how the endocrine-microbiome axis expands the estrobolome concept, showing that gut microbes may alter estrogen recycling, produce hormone-like metabolites, and shape inflammation and tissue environments in hormone-driven cancers. Human evidence remains mostly associative, so the authors call for causal models, longitudinal multi-omics, multi-kingdom profiling, and sex-stratified studies before microbiome-guided cancer strategies enter routine care.

25 Jun 2026

Exercise, not liraglutide alone, drives vascular gains after obesity-related weight loss

A prespecified secondary analysis of the S-LiTE trial found that regular exercise reduced carotid artery wall thickness and circulating levels of inflammatory cytokines in adults with obesity who had already achieved substantial diet-induced weight loss. Liraglutide alone did not significantly improve these vascular or inflammatory markers, while exercise plus liraglutide also improved endothelial function biomarkers.

25 Jun 2026

New review highlights TREM-1 receptor as target for inflammatory diseases

A comprehensive review recently published in Current Molecular Pharmacology consolidates the growing evidence surrounding the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) as a central amplifier of innate immune responses and a promising therapeutic target for a range of inflammatory diseases.

25 Jun 2026

Study identifies key fibrotic cells driving hypertrophic scars

Hypertrophic scars (HS) are abnormal outcomes of wound healing, marked by excessive extracellular matrix (ECM) deposition and impaired scar remodeling.

25 Jun 2026

NVIDIA announces BioNeMo Agent Toolkit — Tools for agents to accelerate scientific discovery

NVIDIA today announced NVIDIA BioNeMo Agent Toolkit, which provides domain-specific tools and skills for the agentic life sciences era.

From Benchling 25 Jun 2026

Maternal blood test reveals prenatal methylation clues linked to autism risk

Researchers found that maternal plasma cell-free DNA methylation patterns in late pregnancy were associated with later autism diagnosis and maternal obesity in a high-likelihood ASD cohort. The findings suggest cfDNA may offer a minimally invasive way to study prenatal epigenetic changes linked to neurodevelopmental risk, but larger validation studies are needed.

25 Jun 2026

Genetic testing could sharply increase demand for ALS specialist care

The availability of genetic testing for amyotrophic lateral sclerosis (ALS) for people with a family member diagnosed with the disease is expected to greatly increase the number of clinic visits to specialized ALS centers over the next decade, according to a study published June 24, 2026, in Neurology Genetics, an official journal of the American Academy of Neurology.

24 Jun 2026